Blueprint Medicines Soars 26% on $9.5 Billion Buyout. Why This Drug Is Key to the Deal.
Latest News
- US service sector unexpectedly contracts in May; inflation heats up
- Crypto Ownership Surges 33% In UK: Why 2025 Could Be Digital Assets' Breakout Year
- Berkshire Hathaway’s Only Fan on Wall Street Stops Cheering. The ‘Buffett Premium’ Fades.
- Apple Stock Is the Mag 7’s Biggest Loser. Today’s Downgrade Just Confirms It.
- These Are JPMorgan's 'Top Picks' for the Internet Sector
- Chart Industries and Flowserve to Merge in $19 Billion Deal. Industrials M&A Steams Ahead.